Immunotherapy plus chemo shows promise for bladder cancer before surgery

NCT ID NCT02690558

Completed Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (gemcitabine and cisplatin) could shrink tumors more effectively before bladder cancer surgery. 39 people with muscle-invasive bladder cancer received the combination before having their bladder removed. The goal was to see if the cancer had shrunk or disappeared by the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab (Keytruda) plus gemcitabine and cisplatin
What this could lead to: If it works, this could lead to a more effective treatment approach for muscle-invasive bladder cancer, potentially reducing tumor size before surgery and improving long-term outcomes.
What could go wrong: This is a small, single-arm Phase 2 trial with only 39 participants, so results may not apply to everyone. Adding immunotherapy to chemo can cause more side effects, and the long-term benefits are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Locations

Duke University Medical Center

Durham, North Carolina, 27710, United States
North Carolina Cancer Hospital (UNC)

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.